Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction

Thrombosis and Haemostasis

Volumn 116, Issue 1, 2016, Pages 96-102

  Thomas, Mark R ^a   Morton, Allison C ^a,b   Hossain, Rashed ^a   Chen, Beining ^a   Luo, Lei ^a   Shahari, Nur Nazihah B Md ^a   Hua, Peng ^a   Beniston, Richard G ^a   Judge, Heather M ^a   Storey, Robert F ^a,b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antiplatelet medications; Morphine; P2Y12 inhibitors; Platelet reactivity; Prasugrel

Indexed keywords

MORPHINE; PRASUGREL; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CROSSING OVER; FEMALE; HUMAN; LOADING DRUG DOSE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PHARMACODYNAMICS; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STOMACH EMPTYING; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECTS; INTESTINE ABSORPTION; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR;

AGED; CROSS-OVER STUDIES; HUMANS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MORPHINE; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; ST ELEVATION MYOCARDIAL INFARCTION; TIME FACTORS;

EID: 84977525421     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH16-02-0102     Document Type: Article

References (21)

1. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 61: e78-e140.
2. Bellemain-Appaix A, Brieger D, Beygui F, et al. New P2Y12 Inhibitors Versus Clopidogrel in Percutaneous Coronary Intervention: A Meta-Analysis. J Am Coll Cardiol 2010; 56: 1542-1551.
3. Frelinger AL, Bhatt DL, Lee RD, et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function. J Am Coll Cardiol 2013; 61: 872-879.
4. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007; 50: 555-562.
5. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J 2007; 153: e9-16.
6. Michelson AD, Frelinger AL, Braunwald E, et al. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
7. Udell JA, Braunwald E, Antman EM, et al. Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation Myocardial Infarction According to Timing of Percutaneous Coronary Intervention: A TRITON-TIMI 38 Subgroup Analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC: Cardiovascular Interventions 2014; 7: 604-612.
8. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001-2015.
9. Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 2013; 61: 1601-1606.
10. Parodi G, Bellandi B, Xanthopoulou I, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv 2014; 8: e0015933.
11. Nimmo WS, Heading RC, Wilson J, et al. Inhibition of gastric emptying and drug absorption by narcotic analgesics. Br J Clin Pharmacol Blackwell Publishing Ltd; 1975; 2: pp 509-513.
12. Angiolillo DJ, Suryadevara S, Capranzano P, et al. Prasugrel: a novel platelet ADP P2Y 12receptor antagonist. A review on its mechanism of action and clinical development. Expert Opin Pharmacother 2008; 9: 2893-2900.
13. Aradi D, Storey RF, Komócsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J 2013; 35: 209-215.
14. Aradi D, Kirtane A, Bonello L, et al. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015; 36: 1762-1771.
15. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomised assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circulation Cardiovasc Interv 2012; 5: 797-804.
16. Hobl E-L, Stimpfl T, Ebner J, et al. Morphine decreases clopidogrel concentrations and effects: a randomised, double-blind, placebo-controlled trial. J Am Coll Cardiol 2014; 63: 630-635.
17. Franchi F, Rollini F, Cho JR, et al. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomised Pharmacokinetic and Pharmacodynamic Investigation. JACC Cardiovasc Interv 2015; 8: 1457-1467.
18. Montalescot G, van ‘t Hof AW, Lapostolle F, et al. Prehospital ticagrelor in STsegment elevation myocardial infarction. N Engl J Med 2014; 371: 1016-1027.
19. Silvain J, Silvain J, Storey R, et al. Impact of morphine administration on ticagrelor- induced platelet inhibition in ST-elevation myocardial infarction patients treated by primary PCI: results from the PRIVATE-ATLANTIC study. J Am Coll Cardiol 2015; 65: 10.
20. Kubica J, Adamski P, Ostrowska M, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomised, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J 2015; ehv547.
21. Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: Results from the CRUSADE Quality Improvement Initiative. Am Heart J 2005; 149: 1043-1049.